X
Aug 16, 2021 09:38 AM (GMT+8) · EqualOcean
Yiouda health learned on the 16th that recently, Zhongshan Kangtian Shenghe Biotechnology Co., Ltd. (hereinafter referred to as "Kangsheng biology") announced the completion of nearly 200 million yuan of round B financing, which was led by China Science and technology innovation, Huangpu pharmaceutical fund and Chuanliu investment, and followed by magpie mountain investment, Xiangshang investment, Zhongshan health industry fund, Huaying investment, Taikang investment and other institutions and old shareholders. This round of financing will be used to strengthen product R & D, improve technological innovation, improve production capacity and high standard industrial order delivery capacity. Kangsheng biology is a global biotechnology company. At present, it has a modern biomedical innovation service platform integrating culture medium development and production, cell line development and GMP pilot production. Kangsheng biology focuses on providing key raw materials for global biopharmaceutical and gene therapy enterprises; And based on customer requirements, provide integrated services from DNA to GMP production in line with FDA / nmpa requirements.

This text is a result of machine translation.